Article
Oncology
Yonggui Tian, Chunli Wen, Zhen Zhang, Yanfen Liu, Feng Li, Qitai Zhao, Chang Yao, Kaiyuan Ni, Shengli Yang, Yi Zhang
Summary: Engineered CAR T cells expressing CXCL9 (CART-CXCL9) enhance cytokine secretion and cytotoxicity, recruit activated T cells, and inhibit angiogenesis, improving CAR T cell efficacy against solid tumors.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Oncology
Feiya Ma, Jensen Vayalil, Grace Lee, Yuqi Wang, Guangyong Peng
Summary: Tumor-derived extracellular vesicles (EVs) are a major factor inducing T cell dysfunction in the tumor microenvironment, playing a crucial role in cancer immunity. By carrying immune suppressive signals, tumor-derived EVs can drive T cell dysfunction and promote tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Ran Chen, Lei Chen, Chaoqun Wang, Hua Zhu, Lijuan Gu, Yuntao Li, Xiaoxing Xiong, Gang Chen, Zhihong Jian
Summary: This paper discusses the limitations and challenges of CAR-T cell therapy in solid tumors, introduces the latest therapeutic strategies and management decisions to overcome these obstacles, aiming to facilitate the widespread use of CAR-T immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Alain E. Andrea, Andrada Chiron, Sarah Mallah, Stephanie Bessoles, Guillaume Sarrabayrouse, Salima Hacein-Bey-Abina
Summary: CAR-T cell therapy has limited efficacy in solid tumors due to the immunosuppressive tumor microenvironment. To overcome this obstacle, researchers are designing new CAR-T cell engineering strategies to enhance the anti-cancer activity of CAR-T cells in hostile environments.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Guangna Liu, Wei Rui, Xueqiang Zhao, Xin Lin
Summary: CAR-T cell therapy has shown successful outcomes in hematological malignancies but faces challenges in treating solid tumors due to immunosuppressive mechanisms in the tumor microenvironment. This review summarized inhibitory factors affecting CAR-T cell function and discussed strategies to enhance CAR-T cell efficacy in solid tumor treatment by targeting these barriers.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Review
Medicine, Research & Experimental
Zaoqu Liu, Zhaokai Zhou, Qin Dang, Hui Xu, Jinxiang Lv, Huanyun Li, Xinwei Han
Summary: Chimeric antigen receptor (CAR)-T cell therapy is a significant advancement in personalized cancer treatment. Although it has achieved considerable success in hematological malignancies, its effectiveness is limited in solid tumors. Recent studies have shown that the tumor immune microenvironment (TIME) has a profound impact on immunotherapeutic response, with immunosuppressive components being a critical obstacle to CAR-T cell activity. However, research on immunosuppressive components also provides inspiration for reshaping the immune environment through engineered CARs.
Article
Multidisciplinary Sciences
Hongxia Li, Emily B. Harrison, Huizhong Li, Koichi Hirabayashi, Jing Chen, Qi-Xiang Li, Jared Gunn, Jared Weiss, Barbara Savoldo, Joel S. Parker, Chad Pecot, Gianpietro Dotti, Hongwei Du
Summary: Therapeutic options for non-small cell lung cancer patients with brain metastases are limited. CAR-T cells targeting B7-H3 and expressing the chemokine receptor CCR2b show improved accumulation in the brain and enhanced anti-tumor activity. This strategy could improve the efficacy of adoptive T-cell therapies in patients with solid tumors presenting with brain metastases.
NATURE COMMUNICATIONS
(2022)
Article
Pharmacology & Pharmacy
Weizhen Li, Yang Zhou, Zhongen Wu, Yaoping Shi, Enming Tian, Yingqi Zhu, Tao Wang, Wei Dou, Xiangjing Meng, Ming Chen, Bo Zhai, Di Zhu
Summary: This study suggests that the combination of CAR T cell therapy targeting EpCAM with a Wnt inhibitor can overcome the limitations of CAR T cells in treating solid tumors.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Fengguang Guo, Jugal K. Das, Koichi S. Kobayashi, Qing-Ming Qin, Thomas A. Ficht, Robert C. Alaniz, Jianxun Song, Paul De Figueiredo
Summary: This study demonstrates that live attenuated bacterial treatment can improve antitumor immunity by remodeling the tumor microenvironment, overcoming cancer resistance to chimeric antigen receptor T-cell therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Gastroenterology & Hepatology
Samantha B. Kemp, Marina Pasca di Magliano, Howard C. Crawford
Summary: Pancreatic ductal adenocarcinoma (PDA) is a nearly universally lethal malignancy characterized by extensive infiltration of immunosuppressive myeloid cells, inhibiting normal immune functions and promoting carcinogenesis. Current immune checkpoint therapy has not been effective in PDA, highlighting the importance of understanding the mechanisms underlying immune suppression in this type of cancer.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Oncology
Qianghua Zhou, Kaiwen Li, Yiming Lai, Kai Yao, Qiong Wang, Xiangyu Zhan, Shirong Peng, Wenli Cai, Wei Yao, Xingxing Zang, Kewei Xu, Jian Huang, Hai Huang
Summary: Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment in PCa. The B7 score, combined with CD8(+) TILs, can be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Javad Masoumi, Abdollah Jafarzadeh, Jalal Abdolalizadeh, Haroon Khan, Jeandet Philippe, Hamed Mirzaei, Hamid Reza Mirzaei
Summary: CSCs are cells with self-renewal ability that initiate tumors and are potential targets for novel anticancer therapeutic agents. CAR-T cells, engineered T cells expressing an artificial receptor specific for TAAs, have shown higher efficiency in cancer treatment by accurately targeting and killing cancer cells.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Oncology
Hena Khalique, Richard Baugh, Arthur Dyer, Eleanor M. Scott, Sally Frost, Sarah Larkin, Janet Lei-Rossmann, Leonard W. Seymour
Summary: PD-L1 BiTE is an effective immunotherapeutic approach to kill PD-L1-positive tumor cells and macrophages while leaving T cells unharmed. This approach activates endogenous T cells within malignant ascites, generates a proinflammatory response, and eliminates cells promoting tumor progression. Using an oncolytic virus for local expression of PD-L1 BiTE also prevents 'on-target off-tumor' systemic toxicities and harnesses immunosuppressive protumor conditions to augment immunotherapy in immunologically 'cold' clinical cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S. Lopez, Rachel H. Ng, Neena Leggett, Vanessa D. Jonsson, Jelani C. Zarif, Peter P. Lee, Xiuli Wang, Catalina Martinez, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman
Summary: This study reveals an alternative mechanism by which the combination of CAR T cells and immune checkpoint blockade modulates the immune landscape of solid tumors to enhance therapeutic efficacy of CAR T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Arthur Xuan Wang, Xiao Jing Ong, Criselle D'Souza, Paul J. Neeson, Joe Jiang Zhu
Summary: Chemotherapy is commonly used before CAR-T cell therapy to improve engraftment. It can deplete immunosuppressive cells, promote a pro-inflammatory tumor microenvironment, disrupt tumor stroma, and improve CAR-T cell recruitment. However, there are challenges and obstacles to achieving effective clinical outcomes with the combination therapy, such as dosage and treatment schedule-dependent effects.
FRONTIERS IN IMMUNOLOGY
(2023)